Cost-Effectiveness of Ribociclib Plus Letrozole for HR+/HER2− Advanced Breast Cancer in Thailand: A Partitioned Survival Analysis Using Real-World Evidence
ClinicoEconomics and Outcomes Research · 2026-11 · Volume 18 · 1-14
DOI: 10.2147/ceor.s649556 ↗Kurz gefasst
Fachartikel in der Zeitschrift ClinicoEconomics and Outcomes Research, 2026-11. Verfasst von Onanong Waleekhachonloet und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Waleekhachonloet, O., Rattanachotphanit, T., Limwattananon, C., Limwattananon, S., Sittibodin, S., & Kuagoolsirirot, T. (2026). Cost-Effectiveness of Ribociclib Plus Letrozole for HR+/HER2− Advanced Breast Cancer in Thailand: A Partitioned Survival Analysis Using Real-World Evidence. ClinicoEconomics and Outcomes Research, Volume 18, 1-14. https://doi.org/10.2147/ceor.s649556
Vancouver
Waleekhachonloet O, Rattanachotphanit T, Limwattananon C, Limwattananon S, Sittibodin S, Kuagoolsirirot T. Cost-Effectiveness of Ribociclib Plus Letrozole for HR+/HER2− Advanced Breast Cancer in Thailand: A Partitioned Survival Analysis Using Real-World Evidence. ClinicoEconomics and Outcomes Research. 2026;Volume 18:1-14. doi:10.2147/ceor.s649556
BibTeX
@article{Waleekhachonloet2026,
author = {Waleekhachonloet, Onanong and Rattanachotphanit, Thananan and Limwattananon, Chulaporn and Limwattananon, Supon and Sittibodin, Surachai and Kuagoolsirirot, Thanyaporn},
title = {Cost-Effectiveness of Ribociclib Plus Letrozole for HR+/HER2− Advanced Breast Cancer in Thailand: A Partitioned Survival Analysis Using Real-World Evidence},
journal = {ClinicoEconomics and Outcomes Research},
year = {2026},
volume = {Volume 18},
pages = {1--14},
doi = {10.2147/ceor.s649556}
}
EUVIMED